Dificid Approved to Treat C. diff Diarrhea
Bacterial infection commonly acquired in hospitals
TUESDAY, May 31 (HealthDay News) -- Dificid (fidaxomicin) has been approved by the U.S. Food and Drug Administration to treat diarrhea associated with Clostridium difficile infection.
The bacterial illness, commonly acquired by the elderly and others with weakened immune systems in hospitals and group settings, is abbreviated C. diff. It is easily passed from person to person by touching contaminated surfaces, the FDA said in a news release.
The infection frequently causes diarrhea, can lead to colitis and other intestinal conditions, and may cause death in severe cases, the agency said. In some people, the illness can recur.
Dificid was evaluated in clinical studies involving 564 people with C. diff-associated diarrhea. More people who took Dificid were still symptom-free three weeks after stopping treatment than those who took a common antibiotic, vancomycin, the FDA said.
Recommended dosage with Dificid is twice daily for 10 days. The most common side effects reported included nausea, vomiting, headache, abdominal pain and diarrhea.
Dificid was developed by Optimer Pharmaceuticals, based in San Diego.
To learn more about this illness, visit the U.S. Centers for Disease Control and Prevention.Scott Roberts Related Articles
- European MRSA Originated in Sub-Saharan Africa, Study Finds
August 29, 2014
- Electrical Pulses to Scalp May Boost Memory: Study
August 28, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.